SMP0124684
View Pathway
|
Levodopa Pahway
Homo sapiens
Matched Description: results in the disruption of the nigrostriatal pathway and thus, decreasing the striatal dopamine … is to increase dopamine in the striatum to increase and improve motor output.
Levodopa by various … transporter-2. When an action potential is generated and reaches the nerve terminal where dopamine is … receptor, which activates the Gi signaling cascade and inhibits the neurons leaving the striatum and … the external globus pallidus to inhibit the subthalamic nucleus, internal globus pallidus and the
|
SMP0422692
View Pathway
|
Oxidative Phosphorylation
Prevotella bivia DSM 20514
Matched Description: acid, resulting in a fumaric acid and ubiquinol.
Ubiquinone interacts with succinic acid through a … cofactors, ferroheme b, 2FE-2S, FAD, and 3Fe-4S iron-sulfur cluster.
Then 2 ubiquinol interact with … oxygen and 4 hydrogen ion through a cytochrome bd-I terminal oxidase resulting in a 4 hydrogen ion … transferred into the periplasmic space, 2 water returned into the cytoplasm and 2 ubiquinone, which … and 4 hydrogen ion through a cytochrome bd-II terminal oxidase resulting in a 4 hydrogen ion
Matched Proteins: Membrane protein involved in the export of O-antigen and teichoic acid
|
SMP0423811
View Pathway
|
Oxidative Phosphorylation
Eikenella corrodens ATCC 23834
Matched Description: acid, resulting in a fumaric acid and ubiquinol.
Ubiquinone interacts with succinic acid through a … cofactors, ferroheme b, 2FE-2S, FAD, and 3Fe-4S iron-sulfur cluster.
Then 2 ubiquinol interact with … oxygen and 4 hydrogen ion through a cytochrome bd-I terminal oxidase resulting in a 4 hydrogen ion … transferred into the periplasmic space, 2 water returned into the cytoplasm and 2 ubiquinone, which … and 4 hydrogen ion through a cytochrome bd-II terminal oxidase resulting in a 4 hydrogen ion
Matched Proteins: Cadmium, cobalt and zinc/H(+)-K(+) antiporter
|
SMP0000640
View Pathway
|
Acetaminophen Metabolism Pathway
Homo sapiens
Matched Description: , accounting for 45-55% of APAP metabolism, and is mediatied by UGT1A1, UGT1A6, UGT1A9, UGT2B15 in the … liver and UGT1A10 in the gut. APAP can also by metabolized via sulfation, accounting for 30-35% of the … , SULT1E1 and SULT2A1. Moreover, APAP can also be activated to form the toxic N-acetyl-p-benzoquinone … imine (NAPQI) under the mediation of CYP3A4, CYP2E1, CYP2D6 CYP1A2, CYP2E1 and CYP2A6.
|
SMP0000957
View Pathway
|
Propanoate Metabolism
Escherichia coli
Matched Description: hydrogen ion, a water molecule and a (2z)-2-aminobut-2-enoate. The latter compound then isomerizes … to a 2-iminobutanoate, This compound then reacts spontaneously with hydrogen ion and a water … molecule resulting in a ammonium and a 2-Ketobutyric acid. The latter compound interacts with CoA through a … pyruvate formate-lyase / 2-ketobutyrate formate-lyase resulting in a formic acid and a propionyl … phosphate. Propionyl-CoA interacts with oxalacetic acid and a water molecule through a 2-methylcitrate
|
SMP0120827
View Pathway
|
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD)
Rattus norvegicus
Matched Description: mitochondrial beta-oxidation of long chain fatty acids. HADHA converts medium- and long-chain 2-enoyl-CoA … compounds into the corresponding 3-ketoacyl-CoA compounds when NAD is present, and acetyl-CoA when … NAD and CoASH are present. Deficiencies in this enzyme prevent the body from converting certain fats … to energy, particularly during periods without food (fasting). Signs and symptoms of LCHAD … deficiency typically manifest during infancy or early childhood and can include feeding difficulties
|
SMP0120608
View Pathway
|
Long-Chain-3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD)
Mus musculus
Matched Description: mitochondrial beta-oxidation of long chain fatty acids. HADHA converts medium- and long-chain 2-enoyl-CoA … compounds into the corresponding 3-ketoacyl-CoA compounds when NAD is present, and acetyl-CoA when … NAD and CoASH are present. Deficiencies in this enzyme prevent the body from converting certain fats … to energy, particularly during periods without food (fasting). Signs and symptoms of LCHAD … deficiency typically manifest during infancy or early childhood and can include feeding difficulties
|
SMP0000608
View Pathway
|
Fluorouracil Metabolism Pathway
Homo sapiens
Matched Description: cancer, pancreatic cancer, breast cancer, and cervical cancer. As a cream, it is used for actinic … keratosis, basal cell carcinoma, and skin warts. Fluorouracil is on the World Health Organization's List … of Essential Medicines, the most effective and safe medicines needed in a health system … . Fluorouracil exerts cytotoxic effects on the cell by direct incorporation into DNA and RNA as well as by inhibiting thymidylate synthase.
|
SMP0125954
View Pathway
|
Paritaprevir Action Pathway
Homo sapiens
Matched Description: target hepatocytes via receptor-mediated endocytosis. The lipoviroparticles attach to LDL-R and SR-B1 … , and then the virus binds to CD81 and subsequently claudin-1 and occludin, which mediate the late … the mature Hepatitis C virion and translated at the rough endoplasmic reticulum into a single … generates nonstructural proteins NS3, NS4A, NS4B, NS5A, and NS5B. These proteins are required in … concentration above their antiviral half-maximal effective concentration (EC50), Paritaprevir and other
|
SMP0125016
View Pathway
|
Hydrocodone Opioid Agonist Action Pathway
Homo sapiens
Matched Description: Hydrocodone is an opioid agonist used as an analgesic and antitussive agent. It is a synthetic … and allergic rhinitis in combination with decongestants, antihistamines, and expectorants … .
Hydrocodone inhibits pain signaling in both the spinal cord and brain. Its actions in the brain also produce … euphoria, respiratory depression, and sedation.
Hydrocodone binds to mu opioid receptors … and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP
|